NantHealth will provide GPS Cancer molecular
analysis to help UCSF better understand the molecular basis of
metastatic breast cancer in order to develop personalized therapy
for individual patients
NantHealth, Inc. (NASDAQ-GS: NH), a next-generation,
evidence-based, personalized healthcare company, today announced
its support for a research study initiated by the University of
California, San Francisco (UCSF) that will use NantHealth’s GPS
Cancer™ panomic molecular analysis test to explore the molecular
basis of patients with metastatic or recurrent breast cancer. The
study will be led by co - principal investigators Hope S. Rugo, MD,
and Denise M. Wolf, PhD, from UCSF.
This year, approximately 40,000 women will die from breast
cancer in the United States1. Despite improvements in early
detection, breast cancer remains a major cause of cancer-related
mortalities. NantHealth and UCSF will collaborate to collect tissue
specimens and clinical data from patients with recurrent or
metastatic breast cancer. The main goal of this project is to
implement a comprehensive molecular profiling pilot study, directed
towards women with metastatic breast cancer, that (1) creates a
work flow to establish the feasibility of real time comprehensive
profiling to support clinical decision making, (2) benefits
participating patients by evaluating ‘actionable’ biomarkers and
returning results, and (3) records whether the results were
considered useful and impacted care.
“It is an exciting time for us as we embark on this partnership
with Dr. Patrick Soon-Shiong and NantHealth to further investigate
metastatic breast cancer,” said Dr. Hope S. Rugo, clinical
professor of the Department of Medicine (Hematology/Oncology) and
director of the Breast Oncology Clinical Trials Program at UCSF and
principal investigator of this study. “We understand that every
patient responds to treatment differently, making it imperative for
us to develop effective, personalized treatment options to fight
stage IV breast cancer. My team and I are looking forward to this
study and are confident that we will have a better understanding of
how molecular profiling plays into physicians’ treatment
decisions.”
This study will allow UCSF researchers to utilize advancements
made in molecular technology to examine the potential clinical
feasibility of molecular profiling, including gene mutations, gene
and protein expression in the context of patient care. The biopsy
materials collected will also allow researchers to examine immune
markers within the tumor architecture. Through this partnership,
UCSF will increase its access to exceptional molecular profiling,
combined with exploratory markers.
“UCSF’s health science research is recognized worldwide for
pushing scientific boundaries and they have been known for their
thoughtful and strategic collaborations that aim to advance the way
diseases are treated,” said Patrick Soon-Shiong, MD, Chairman and
CEO of NantHealth. “As we look to better understand the underlying
cause of stage IV breast cancer, I am certain that Drs. Rugo and
Wolf and their team of investigators have the knowledge, resources
and expertise to be successful in exploring the relationship of
immune profiling with tumor characteristics and molecular profiling
in patients diagnosed with this form of breast cancer.”
University of California, San Francisco DisclaimerThe
information stated above was prepared by NantHealth, Inc. and
reflects solely the opinion of the corporation. Nothing in this
statement shall be construed to imply any support or endorsement of
NantHealth, or any of its products, by The Regents of the
University of California, its officers, agents and employees.
About University of California, San FranciscoUC San
Francisco (UCSF) is a leading university dedicated to promoting
health worldwide through advanced biomedical research,
graduate-level education in the life sciences and health
professions, and excellence in patient care. It includes top-ranked
graduate schools of dentistry, medicine, nursing and pharmacy; a
graduate division with nationally renowned programs in basic,
biomedical, translational and population sciences; and a preeminent
biomedical research enterprise. It also includes UCSF Health, which
comprises three top-ranked hospitals, UCSF Medical
Center and UCSF Benioff Children’s Hospitals in San
Francisco and Oakland, and other partner and affiliated
hospitals and healthcare providers throughout the Bay Area.
About GPS Cancer™GPS Cancer™ is a unique, molecular scan
available through NantHealth. GPS Cancer integrates whole genome
(DNA) sequencing, whole transcriptome (RNA) sequencing, and
quantitative proteomics through mass spectrometry, providing
oncologists with a comprehensive molecular profile of a patient's
cancer and an assessment of protein pathway function to inform
personalized treatment strategies. GPS Cancer scanning is conducted
in CLIA-certified and CAP-accredited laboratories, and is a key
enabler for Cancer Breakthroughs 2020, the world's most
comprehensive cancer collaborative initiative seeking to accelerate
the potential of combination immunotherapy as the next generation
standard of care in cancer patients. For more information,
visit www.gpscancer.com.
Cautionary Note Concerning Forward-Looking StatementsThis
press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
including, among others, statements regarding the capabilities and
anticipated utility of our GPS Cancer, including predicting patient
response and resistance to therapeutics, enabling diagnoses by
physicians and accelerating efforts to bring novel combinations of
therapeutic agents to cancer patients. Forward-looking statements
are subject to numerous risks and uncertainties that could cause
actual results to differ materially from currently anticipated
results. Factors that may cause future results to differ materially
from management’s current expectations include, among other things,
that GPS Cancer may not perform as anticipated, that sufficient
physicians may not adopt GPS Cancer to assist their diagnoses or
that healthcare payers may not provide reimbursement for GPS Cancer
as expected. Our business is subject to numerous additional risks
and uncertainties, including, among others, risks relating to
market acceptance of our products; our ability to successfully
launch new products and applications; competition; our sales,
marketing and distribution capabilities; our planned sales,
marketing, and research and development activities; unanticipated
increases in costs or expenses; and risks associated with
international operations. Information on these and additional
risks, uncertainties, and other information affecting our business
and operating results can be found in our existing and future
filings with the Securities and Exchange Commission. These
forward-looking statements speak only as of the date hereof. We
disclaim any obligation to update these forward-looking statements
except as may be required by law.
About NantHealth, Inc.NantHealth, Inc., a member of the
NantWorks ecosystem of companies, is a next-generation,
evidence-based, personalized healthcare company enabling improved
patient outcomes and more effective treatment decisions for
critical illnesses. NantHealth's unique systems-based approach to
personalized healthcare applies novel diagnostics tailored to the
specific molecular profiles of patient tissues and integrates this
molecular data in a clinical setting with large-scale, real-time
biometric signal and phenotypic data to track patient outcomes and
deliver precision medicine. For nearly a decade, NantHealth has
developed an adaptive learning system, which includes its unique
software, middleware and hardware systems infrastructure that
collects, indexes, analyzes and interprets billions of molecular,
clinical, operational and financial data points derived from novel
and traditional sources, continuously improves decision-making and
further optimizes our clinical pathways and decision algorithms
over time. For more information please
visit www.nanthealth.com and follow Dr. Soon-Shiong on
Twitter @DrPatSoonShiong.
1
http://www.breastcancer.org/symptoms/understand_bc/statistics
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171204005379/en/
NantWorksJen Hodsonjhodson@nantworks.com
NantHealth (NASDAQ:NH)
Historical Stock Chart
From Mar 2024 to Apr 2024
NantHealth (NASDAQ:NH)
Historical Stock Chart
From Apr 2023 to Apr 2024